<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
 
 

On Demand Webinar

 
Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models


KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy, and understanding why resistance inevitably emerges, remains one of the central challenges in oncology drug development.

In this webinar, we present findings from a 50+ model KRAS-mutant PDX cohort spanning NSCLC, CRC and PDAC. Drawing on multi-omic characterisation and integrated genomic analysis, our expert speakers explore how KRAS allele type, co-driver mutations, and prior treatment history shape tumour response to pan-RAS(ON) inhibition.

In 30 minutes, the webinar covers;

  • intrinsic sensitivity patterns across indications<
  • differential gene expression signatures that distinguish responders from non-responders
  • longitudinal data capturing how acquired resistance develops under continuous treatment pressure.

Together, these findings illustrate how deeply annotated PDX platforms can define the molecular determinants of RAS inhibitor response and inform rational combination strategies.

This webinar is designed for preclinical and translational leaders in the pharmaceutical and biotech industries working in the KRAS space who want a grounded, data-driven perspective on where the field is heading and how patient-derived platforms are shaping drug development decisions.

Watch Now!

Watch the Webinar

Meet Our Presenters:

Michael Ritchie, Scientific Advisor, Champions Oncology

Mike Ritchie has over 20 years of experience in oncology research and drug development. He earned his PhD in Biochemistry from Temple University School of Medicine and completed a postdoctoral fellowship in Neuroscience at Harvard Medical School. Earlier in his career, he led therapeutic programs at Pfizer, and for the past decade at Champions Oncology he has advanced the use of patient-derived models and multi-omic platforms. A recognized thought leader, he shares insights on translational models, radiopharmaceuticals, and AI-driven analytics to accelerate oncology pipelines and reduce risk.

 

Alex Moreau,VP, Global Data Partnerships, 
Champions Oncology

Alex Moreau, PhD, is an accomplished scientific leader. He earned his doctorate at Université Paris-Sud (Paris-Saclay), where his research led to multiple peer-reviewed publications. He completed his postdoctoral research at University College London. Dr. Moreau now serves as Vice President of Business Development at Champions Oncology, leveraging extensive experience bridging science and industry to drive innovation in oncology and translational research.